ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SSilverstein
|
4 |
2.1K |
3 |
13/01/24 |
13/01/24 |
ASX - By Stock
|
4
|
2.1K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Change in substantial holding
|
|
SSilverstein
|
14 |
7.1K |
1 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
14
|
7.1K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
0 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
82
|
25K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
0 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
82
|
25K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Appointment of Non-executive Director
|
|
SSilverstein
|
4 |
960 |
2 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
4
|
960
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
0 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
82
|
25K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
1 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
82
|
25K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
0 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
82
|
25K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
0 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
82
|
25K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
0 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
82
|
25K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
2 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
82
|
25K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
2 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
82
|
25K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
1 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
82
|
25K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
3 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
82
|
25K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
0 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
82
|
25K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
SSilverstein
|
82 |
25K |
0 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
82
|
25K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Change in substantial holding
|
|
SSilverstein
|
6 |
2.0K |
0 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
6
|
2.0K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Becoming a substantial holder
|
|
SSilverstein
|
17 |
6.1K |
0 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
17
|
6.1K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Becoming a substantial holder
|
|
SSilverstein
|
17 |
6.1K |
0 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
17
|
6.1K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Becoming a substantial holder
|
|
SSilverstein
|
17 |
6.1K |
0 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
17
|
6.1K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Change of Director's Interest Notice
|
|
SSilverstein
|
8 |
2.3K |
2 |
26/08/23 |
26/08/23 |
ASX - By Stock
|
8
|
2.3K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex to close IIH Evolve Phase III Clinical Trial
|
|
SSilverstein
|
41 |
9.9K |
0 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
41
|
9.9K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex to close IIH Evolve Phase III Clinical Trial
|
|
SSilverstein
|
41 |
9.9K |
1 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
41
|
9.9K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex to close IIH Evolve Phase III Clinical Trial
|
|
SSilverstein
|
41 |
9.9K |
0 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
41
|
9.9K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex to close IIH Evolve Phase III Clinical Trial
|
|
SSilverstein
|
41 |
9.9K |
1 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
41
|
9.9K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Trading Halt
|
|
SSilverstein
|
18 |
4.9K |
0 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
18
|
4.9K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Trading Halt
|
|
SSilverstein
|
18 |
4.9K |
0 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
18
|
4.9K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SSilverstein
|
29 |
10K |
1 |
24/07/23 |
24/07/23 |
ASX - By Stock
|
29
|
10K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Trial Still Recruiting
|
|
SSilverstein
|
2 |
785 |
0 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
2
|
785
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Twiggy's Invex Therapeutics | The Imminent Coin Flip
|
|
SSilverstein
|
219 |
47K |
1 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
219
|
47K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Twiggy's Invex Therapeutics | The Imminent Coin Flip
|
|
SSilverstein
|
219 |
47K |
2 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
219
|
47K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Twiggy's Invex Therapeutics | The Imminent Coin Flip
|
|
SSilverstein
|
219 |
47K |
3 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
219
|
47K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
SSilverstein
|
77 |
21K |
0 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
21K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
SSilverstein
|
77 |
21K |
1 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
21K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
SSilverstein
|
77 |
21K |
1 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
21K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
SSilverstein
|
77 |
21K |
1 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
21K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
SSilverstein
|
77 |
21K |
1 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
21K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
SSilverstein
|
77 |
21K |
1 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
21K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
2 |
02/07/23 |
02/07/23 |
ASX - By Stock
|
224
|
56K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
1 |
01/07/23 |
01/07/23 |
ASX - By Stock
|
224
|
56K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
2 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
56K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
0 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
56K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
6 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
56K
|
6
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
5 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
56K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
3 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
56K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
2 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
56K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
3 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
56K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
9 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
56K
|
9
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
2 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
56K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
SSilverstein
|
224 |
56K |
0 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
56K
|
0
|
|